Nutrivert Inc. — SEC Form D Filing

Nutrivert Inc. filed an SEC Form D on April 29, 2026, reporting $2.37M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
April 29, 2026
Amount reported
$2.37M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://www.nutrivertglobal.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

The high volume and cost of veterinary antibiotics in livestock production lead to a need for alternative solutions, especially since antibiotics are sometimes used at subtherapeutic levels that promote growth rather than address bacterial diseases.

Solution

Nutrivert Inc. is developing Nutrivert LDPP, a synthetic non-antibiotic compound that mimics bacterial cell components to promote growth and feed efficiency in livestock, while reducing inflammation.

Why now

With increasing awareness and regulations surrounding antibiotic use in livestock, there is a pressing need for effective alternatives that ensure animal health and food safety.

Verdict

Investors said yes at this moment because Nutrivert's narrative compellingly tied into rising regulatory pressures and consumer demand for antibiotic-free livestock solutions, not because the technology was clearly differentiated from existing alternatives. They were betting on growing momentum toward sustainable practices in agriculture, but the limited durability stems from competition with established players and potential for regulatory fatigue over time.

Source: SEC EDGAR Form D filing